2011 Fiscal Year Final Research Report
Analysis of factors that regulate effector T cell and regulatory T cell recruitment to the skin
| Project/Area Number |
21390327
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Dermatology
|
|---|
| Research Institution | Kyorin University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
MIZUKAWA Yoshiko 杏林大学, 医学部, 助教 (50301479)
TAKAHASHI Ryo 杏林大学, 医学部, 助教 (00317091)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Keywords | effector T 細胞 / regulatory T 細胞 / 皮膚ホーミング / 薬疹 / ヘルペスウイルス |
|---|
| Research Abstract |
In this study, we investigated which factors can determine the balance between effector T cells (Teff) and regulator T cells (Treg) in the inflammatory sites. In fixed drug eruption (FDE) lesions that spontaneously resolve, mast cells expressing high levels of IL-16 are abundantly detected, thereby inducing Treg recruitment to the inflammatory site. In contrast, the paucity of mast cells expressing IL-16 in the SJS/TEN lesions that exibit severe immunopathology made Treg impossible to migrate into the inflammatory site. On the other hand, the abundance of mast cells expressing IL-16 was detrimental to tumor regression through the induction of Treg recruitment. Repeated application of imiquimod able to stimulate TLR7/8 caused an increase in IL-17 expressing mast cells and a profound decrease in the Treg/Teff ratio, which was associated with tumor regression. Thus, the balance between Treg and Teff in the inflammatory site can be determined by mast cells resident in the lesion: if they preferentially produce IL-16, the lesions spontaneously resolve; but if they produce IL-17, immunopathology ensues.
|
